Skip to main content

BIO-TECHNE Corp

For the period ended Sep 30, 2026. Filed Nov 6, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 6, 2026

TECH$72.83+0.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

​​​​​​​
​ · ​ ​ ​ · September 30, · ​ · ​ · ​
​ · ​ · 2026 · ​ · June 30,
​ · ​ · (unaudited) · ​ · 2026
ASSETS · ​ · ​ · ​ · ​
Current assets: · ​ · ​ · ​ · ​
Cash and cash equivalents​$350,036​$264,712
Accounts receivable, less allowances of $4,832 and $4,644, respectively​203,058​216,585
Inventories​197,667​195,744
Other current assets​​74,069​67,360
Total current assets​824,830​744,401
​​​​​​​
Property and equipment, net​227,764​231,836
Right-of-use assets​64,408​67,333
Goodwill​972,074​975,355
Intangible assets, net​287,035​303,465
Other assets​260,709​264,336
Total assets​$2,636,820​$2,586,726
LIABILITIES AND SHAREHOLDERS’ EQUITY​​​​
Current liabilities:​​​​
Trade accounts payable​$30,996​$26,699
Salaries, wages and related accruals​44,347​57,918
Accrued expenses​19,751​20,458
Short-term debt obligations​​200,000​​—
Contract liabilities​31,758​36,072
Income taxes payable​2,708​3,593
Operating lease liabilities - current​14,992​14,935
Other current liabilities​16,717​4,025
Total current liabilities​361,269​163,700
​​​​​​​
Deferred income taxes​23,506​19,308
Long-term debt obligations​—​200,000
Operating lease liabilities​70,563​74,152
Other long-term liabilities​15,793​21,345
​​​​​
Shareholders’ equity:​​​​​​
Undesignated capital stock, par value $.01 per share; authorized 5,000,000 shares; none issued or outstanding​—​—
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,053,885 and 156,095,113 respectively​1,571​1,561
Additional paid-in capital​1,082,629​1,033,052
Retained earnings​1,152,686​1,144,188
Accumulated other comprehensive loss​(71,197)​(70,580)
Total shareholders’ equity​2,165,689​2,108,221
Total liabilities and shareholders’ equity​$2,636,820​$2,586,726
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.